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Abstract
Proteoglycan (PG) aggrecan-induced arthritis (PGIA) is a murine model of rheumatoid arthritis (RA).
Although BALB/c and DBA/2 mice share the same MHC (H-2d) haplotype, the BALB/c strain is
susceptible to PGIA, while DBA/2 mice are resistant. Therefore, these two inbred mouse strains
provide an opportunity to study arthritis susceptibility factors excluding the effects of MHC-
associated genetic components. The goal of this study was to monitor changes in the cellular
composition and activation state following intra-peritoneal (i.p.) immunization to induce PGIA;
additionally, we sought to identify new susceptibility factors by comparing PG-induced immune
responses in BALB/c and DBA/2 mice. Upon i.p. PG injection, resident naive B1 cells are replaced by
both T cells and conventional B cells in the peritoneum of BALB/c mice. These peritoneal T cells
produce IFNg and IL-17, cytokines shown to be important in RA and corresponding arthritis models.
Moreover, peritoneal cells can adoptively transfer PGIA to SCID mice, demonstrating their
arthritogenic properties. Our results indicate that repeatedly injected antigen leads to the recruitment
and activation of immune cells in the peritoneum; these cells then trigger the effector phase of the
disease. The migration and activation of Th1/Th17 cells in the peritoneal cavity in response to PG
immunization, which did not occur in the arthritis-resistant DBA/2 strain, may be critical factors of
arthritis susceptibility in BALB/c mice.
Introduction
Proteoglycan (PG) aggrecan-induced arthritis (PGIA) is one
of the murine models of rheumatoid arthritis (RA). Repeated
intra-peritoneal (i.p.) immunization with human cartilage PG
(aggrecan) leads to joint inﬂammation, progressive cartilage
destruction, bone erosion and ankylosis in diarthrodial joints
of genetically susceptible BALB/c mice (1). Autoimmune fea-
tures of PGIA, such as autoreactivity, T and B cell involve-
ment and the cytokine proﬁle in serum and synovial ﬂuid
closely resemble RA (2). Additional features common to RA
are that this model includes early involvement of small syno-
vial joints, similar X-ray and histopathologic abnormalities of
peripheral joints, greater susceptibility of aging females,
dominant, but not exclusive, effect of MHC, the polygenic
character and the recessive inheritance of the disease
[reviewed in (2)]. Immunization with human cartilage PG
aggrecan leads to the breakdown of self-tolerance, and it
triggers an autoimmune response to murine cartilage PG
due to the presence of cross-reactive epitopes in human
and murine PGs (3–5).
The i.p. route of immunization appears to be critical for
disease induction in the PGIA model. Although intra-dermal,
subcutaneous or intra-muscular administration of the same
PG antigen induces massive T and B cell responses, the se-
verity of arthritis is weaker. Therefore, it is a logical approach
to study immunological events in the peritoneum that may
determine the development and progression of this autoim-
mune disease.
The peritoneal cavity is a unique microenvironment, lined
by a serous membrane that consists of a mesothelial layer
and sub-mesothelial connective tissue, containing blood
and lymphatic vessels, and lymphoid tissue (6). ‘Milky spots’
on the human omentum, containing mostly macrophages
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foci within the peritoneal cavity (7). The peritoneal ﬂuid con-
tains different types of immune cells, such as macrophages,
lymphocytes and dendritic cells (6). B1 lymphocytes repre-
sent a major cell population in the peritoneum; however, this
cell type is rare in other tissues (8). A major function of these
B1 cells is thought to be the production of IgM (9), although
effective antigen presentation is another signiﬁcant feature
of these B1 cells (10, 11). Furthermore, two functionally dif-
ferent B1 cell sub-populations (B1a/b) can be deﬁned based
on the expression of the CD5 molecule, a cell surface recep-
tor that is otherwise expressed by T cells (12).
Besides the site of immunization (antigen entry), the direction
of the immune response is largely determined by the adjuvant.
For example, CFA and dimethyldioctadecyl-ammonium bro-
mide (DDA) are known to induce Th1 type immune responses,
while alum adjuvant favors Th2 polarization (13–15). Adjuvants
exert these effects mainly by activating the cells of innate im-
munity (14, 16). DDA enhances both cellular and humoral im-
mune responses when injected i.p. but primarily supports
cellular immunity when administered subcutaneously (17).
PGIA can be induced in genetically susceptible BALB/c
mice, however, most other strains are resistant, for example
the MHC-matched DBA/2 is a resistant strain (1, 18, 19). Al-
though the difference in arthritis susceptibility between these
two strains has been known for >20 years (18) and the fun-
damental cellular and immunological mechanisms leading
to the development of PGIA have been described [see for
review, ref. (2)], the most critical susceptibility factors have
not been elucidated. PGIA is a T cell-dependent, B cell-
and/or antibody-mediated disease (2, 18). The disease can-
not be adoptively transferred by T cells, B cells or antibodies
alone to naive BALB/c or SCID mice; successful transfer
requires both T cells and either B cells or antibodies from ar-
thritic animals (5, 20). A shift toward a Th1-dominant cytokine
proﬁle is necessary for disease development (21, 22), and
IL-4 has been shown to act as a negative regulator, or a pro-
tective cytokine, in PGIA (23).
The induction phase of this autoimmune disease begins
with the activation of PG-speciﬁc T and B cells, eventually
overcoming self-tolerance; this takes place during the immu-
nization regime (18). Therefore, we chose to characterize the
early events following i.p. immunization, when joint inﬂamma-
tion was not yet present. We then extended our study by an-
alyzing changes in cellular composition, activation markers,
cytokine production, T cell response and antibody produc-
tion during the entire immunization period.
Here we report that the earliest events in the peritoneum
following i.p. PG immunization are the disappearance of res-
ident naive B1 cells and their replacement by T cells and
conventional B cells in BALB/c mice. This re-organization of
the cellular composition following repeated injections of anti-
gen suggests that the generation of activated effector cells,
beginning in the peritoneum, triggers the effector phase of
the disease. Moreover, the arthritogenic potential of these
activated peritoneal cells is conﬁrmed by their ability to
adoptively transfer PGIA to SCID mice. Adjuvant DDA plays
a crucial role in initiating the change of cellular composition
in the peritoneal cavity, but DDA itself is not capable of dis-
ease induction. Changes in the cellular composition in re-
sponse to PG injection, which do not occur in the MHC-
matched arthritis-resistant DBA/2 strain, appear to determine
the arthritis susceptibility of BALB/c mice to PGIA.
Materials and methods
Chemicals
All chemicals, unless indicated otherwise, were purchased
from Sigma Chemical Co. (St Louis, MO, USA) or Fisher Sci-
entiﬁc (Chicago, IL, USA). Mouse recombinant cytokines
and ELISA kits were purchased from R&D Systems (Minne-
apolis, MN, USA) or BD Biosciences (San Jose, CA, USA).
PBS (pH 7.4) was used for washing and short-term storage
of cells until use. Cell surface labeling with mAbs was car-
ried out in ﬂow cytometry wash buffer (PBS containing 0.1%
NaN3 and 0.1% BSA). Intracellular FoxP3 labeling was per-
formed in permeabilization buffer after ﬁxation of surface-
stained cells (eBioscience, San Diego, CA, USA).
Antigen, animals and immunization
Articular cartilage was collected from patients undergoing
knee joint replacement surgery. The collection of cartilage
from consenting patients was approved by the Institutional
Review Board of Rush University Medical Center. Cartilage
PG (aggrecan) was extracted and depleted of glycosamino-
glycan side chains as described (24).
All animal procedures were conducted under a protocol
approved by the Institutional Animal Care and Use Commit-
tee of Rush University Medical Center. Female BALB/c and
DBA/2 mice of 16–20 weeks of age and sex- and age-
matched SCID mice of BALB/c background (NCI/NCrC.B-
17-scid/scid; henceforth SCID) were purchased from the Na-
tional Cancer Institute (Fredrick, MD, USA). Mice were im-
munized via i.p. injection with an emulsion of cartilage PG
(100 lg protein) and 2 mg DDA adjuvant on days 0, 21 and
42 (24). Groups of animals were sacriﬁced 5, 10 and 20
days after the ﬁrst, second and third immunizations, respec-
tively. Adoptive transfer of PGIA from BALB/c to SCID mice
was performed as described (20). Brieﬂy, 13 3 10
6 perito-
neal lavage ﬂuid (PLF) cells, harvested 10 days after the
ﬁrst, second and third immunization, were injected i.p. with
100 lg PG into SCID mice, twice 10–14 days apart. In pre-
liminary experiments, PLF cells of PG/DDA-immunized DBA/
2 mice (after four immunizations) were also used for adop-
tive transfer, and cell compositions of the PLF were deter-
mined in CD44- and CD62L-deﬁcient BALB/c mice after PG/
DDA injections.
Clinical assessment of arthritis
PG-immunized BALB/c, DBA/2 and recipient SCID mice were
examined three to four times a week for clinical symptoms of ar-
thritis. The time of onset and incidence of arthritis were
recorded, and severity was scored visually based upon the
swelling and redness of each paw, ranging from zero to four,
yielding a maximum severity score of 16 per mouse (1, 18, 24).
mAbs
The following ﬂuorochrome-labeled or biotinylated mAbs were
purchased from BD Biosciences: FITC-conjugated Armenian
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anti-mouse CD8 (clone 53-6.7), PerCP–Cy5.5-conjugated
rat anti-mouse CD4 (clone RM4-5), PE–Cy7-conjugated rat
anti-mouse B220 (clone RA3-6B2), Allophycocyanin (APC)-
conjugated rat anti-mouse CD25 (clone PC61), APC–
Cy7-conjugated Armenian hamster anti-mouse CD3 (clone
145-2C11), FITC-conjugated rat anti-mouse IgD (clone 11-
26c.2a), PE-conjugated rat anti-mouse CD43 (clone S7),
PerCP–Cy5.5-conjugated rat anti-mouse IgM (clone R6-60.2),
PE–Cy7-conjugated rat anti-mouse CD19 (clone 1D3),
APC-conjugated rat anti-mouse CD5 (clone 53-7.3), biotin-
conjugated rat anti-mouse CD23 (clone B3B4), Alexa Fluor
488-conjugated rat anti-mouse CD44 (clone IM7) and
PE-conjugated rat anti-mouse CD62L (clone MEL-14). PE-
conjugated rat anti-mouse FoxP3 (clone FJK-16s) was pur-
chased from eBioscience. Biotinylated mAbs were detected
by the use of APC–Cy7-conjugated streptavidin.
Fluorescent cell surface labeling
We used a three- to six-color labeling technique for the si-
multaneous detection of cell surface and intracellular mole-
cules in cells harvested from the PLF and spleen of mice.
Brieﬂy, 1 3 10
6 cells were seeded in 96-well U-bottom assay
plates (BD Falcon). Fc receptors were blocked with anti-
CD16/32 (FcBlock, BD Biosciences) at 4 C for 15 min, and
cells were then incubated with mAb cocktails in 100 ll ﬂow
cytometry staining buffer at 4 C in the dark for 30 min. Cells
were washed twice and ﬁnally re-suspended in 200 llo f
0.1% formaldehyde in PBS. If biotinylated mAb was used,
ﬂuorochrome-labeled streptavidin was added to the samples
after washing, and cells were then incubated at 4 C in the
dark for another 30 min. Intracellular FoxP3 was stained after
ﬁxation and permeabilization of cells. Isotype-matched con-
trol IgG (rat or hamster) for each color was used for back-
ground staining.
Flow cytometric measurement and phenotypic analysis,
deﬁnition of cell populations
Samples were measured and analyzed using a FACS Canto II
ﬂow cytometer and FACS DIVA software (BD Biosciences).
Acquisition was performed by gating on lymphoid cells within
forward/side-scatter dot plots. Cell surface marker-deﬁned
populations were as follows—CD3+: total Tcells; CD3+ CD4+:
CD4+ T cells; CD3+ CD8+: CD8+ T cells; CD4+ CD25+
FoxP3+: regulatory Tcells (Tregs); B220+: total B cells; IgD
low
IgM
high CD19+ CD23 CD5+/: B1 cells (B1a/b) and IgD
high
IgM
low CD19+ CD23+: conventional B2 cells (25). Speciﬁc
cell proportions were expressed as percentage of total cells
unless otherwise stated. Data were collected from 10 000
cells within the lymphoid gate in each sample. We used ﬂuo-
rescent histogram plots to compare mean ﬂuorescence in-
tensities of different samples and to calculate the
proportions of positively stained cells.
Measurement of PG-speciﬁc antibodies and T cell response
Serum samples, PLF and spleen cells were harvested from
BALB/c and DBA/2 mice before and at different time points
after each immunization and also from adoptively transferred
SCID mice 40–50 days after the second cell transfer. PG-
speciﬁc antibodies were measured using ELISA as de-
scribed (20, 24). In brief, sera were diluted at the range of
1:100–1:102400, and PG-bound antibodies were detected
with peroxidase-conjugated rabbit anti-mouse IgG1 or
IgG2a (Zymed Laboratories, San Francisco, CA, USA).
Antigen-speciﬁc T cell responses were measured in qua-
druplicate samples of spleen cells (3 3 10
5 cells per well in
200 ll on 96-well plates) cultured in the absence or presence
of 50 lg human PG protein per milliliter. T cell proliferation
was assessed using [
3H]thymidine incorporation on day 5 of
culture (20, 26). Spontaneous and antigen-speciﬁc production
of IL-4 (detection level: 10 pg ml
1), IL-6 (detection level:
20 pg ml
1), IL-12/23 p40 (detection level: 30 pg ml
1), IL-17
(detection level: 20 pg ml
1), tumor necrosis factor a (TNFa)
(detection level: 50 pg ml
1) and IFNc (detection level: 80 pg
ml
1) was measured in PLF and spleen cell culture superna-
tants (1.8 3 10
6 cells per well in 600 ll on 48-well plates)
harvested on day 5 using capture ELISAs (from BD Bioscien-
ces or R&D Systems), and the results were expressed as
cytokine (picograms) secreted by 10
6 cells (26).
Statistical analysis
Descriptive statistics were used to determine group means
and standard error of the mean (SEM) (mean 6 SEM) unless
otherwise stated. The difference between two groups was
tested for statistical signiﬁcance using Student’s t-test, and
the difference among three or more groups was tested using
analysis of variance. A P <0.05 value was considered to be
statistically signiﬁcant.
Results
Immunophenotypic characterization of naive BALB/c and
DBA/2 mice
Since basal immunologic traits of mice may affect the im-
mune response to antigen, in this case PG, which causes ar-
thritis, we ﬁrst assessed the cellular composition of the PLF,
the ﬁrst site of antigen entry after i.p. injection, and the
spleen, which is involved later in the systemic response, in
naive BALB/c mice, focusing on lymphoid cell types.
Table 1 compares the distribution and phenotypic proper-
ties of T and B cells in these two compartments in naive
BALB/c mice. The CD4+/CD8+ T cell ratio was higher in the
PLF than the spleen, but the CD62L
high/CD44
high CD4+ ratio,
which denotes resting and activated CD4+ T cells, respec-
tively, was similar in the two compartments (Table 1). A more
detailed cell surface marker analysis of the B cell pool in na-
ive BALB/c mice showed that in the PLF, a majority of B cells
belonged to the B1 cell sub-population, while the spleen
contained more conventional B (B2) cells (Table 1). In the
PLF, the CD5+/CD5 B1 cell ratio was 0.145 (Table 1), indi-
cating the dominance of CD5 B1 cells in the naive perito-
neal milieu.
In MHC-matched, but PGIA-resistant, naive DBA/2 mice,
we found signiﬁcantly fewer T cells but similar numbers of B
cells as in naive BALB/c mice, both in the PLF and the
spleen (Tables 1 and 2). The CD4+:CD8+ T cell ratio was
higher in DBA/2 than in BALB/c mice (Tables 1 and 2). There
were signiﬁcantly fewer CD62L
high CD4+ T cells, CD44
high
CD4+ T cells and Tregs in the spleen of naive DBA/2 mice
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the B1:B2 (conventional) cell ratio was higher, but the
CD5+/CD5 B1 cell ratio was lower in DBA/2 mice than in
BALB/c mice (Tables 1 and 2).
Changes in cellular composition of the PLF upon i.p.
immunization with PG
The most efﬁcient way of immunization leading to PGIA is
the i.p. injection of PG with either CFA (1) or DDA (14). The
use of DDA, instead of CFA, however, became a routine pro-
cess lately to avoid the side effects of CFA including the
complicating effects of heat shock proteins, bacterial cell
wall components etc. present in mycobacteria preparations
(14). The peritoneal cavity is the entry site of the antigen,
where the cells of the immune system ﬁrst encounter PG
and adjuvant. Therefore, we monitored the changes in cellu-
lar composition of the PLF at different time points during im-
munization with PG and DDA, as well as when DDA
adjuvant was injected without antigen in both BALB/c and
DBA/2 mice.
The number of T cells in BALB/c PLF increased signiﬁcantly
compared with naive animals by 10–20 days after the ﬁrst PG
injection (Fig. 1A and G). Most of these T cells were CD4+,
and 26.4 6 5.4% of the CD4+ cells expressed high levels of
CD25 already at day 5 after the ﬁrst i.p. injection of PG in
DDA (data not shown). There was a 2-fold increase (up to
79.3 6 2.4%) in the CD44
high CD4+ cell percentage, com-
pared with that measured in naive animals (data not shown).
After a transient decrease, detected between the second
and third i.p. PG/DDA injections, the number of T cells in-
creased again after the third immunization in the PLF of
BALB/c mice (Fig. 1A and G). In the PLF of DBA/2 mice, the
T cell number remained lower than in BALB/c through the
whole immunization period. However, there were transient but
signiﬁcant increases in the T cell number after the second
and third i.p. PG + DDA injections compared with the naive
DBA/2 PLF (Fig. 1A).
In contrast to the signiﬁcant expansion of T cells in the
peritoneal cavity of BALB/c mice in response to i.p. immuni-
zation, the number of B1 cells (IgD
low IgM
high CD19+
CD23) measured in the PLF of naive mice declined from
>10
6 cells to <10
5 cells within 5 days and remained at a sig-
niﬁcantly lower level throughout the immunization period
(Fig. 1B and G). The number of conventional B cells (IgD
high,
IgM
low, CD19+ and CD23+) dropped after each i.p. injection
but always returned close to the levels measured before im-
munization (Fig. 1C and G). Changes in the B1 cell and con-
ventional B cell numbers showed similar kinetics after i.p.
PG injections during the entire immunization period in both
BALB/c and DBA/2 mice (Fig. 1B and C).
To further dissect whether the changes in cellular compo-
sition described above could be attributed to the antigen
(PG) or the adjuvant (DDA), we repeated the same immuni-
zation protocol with PBS/DDA and monitored the same
parameters. We found that DDA alone caused very similar
changes in cellular composition (increased T cell and con-
ventional B cell numbers and decreased B1 cell numbers)
in the peritoneal cavity of BALB/c mice to what was ob-
served when the antigen (PG) was also present (Fig. 1D–F).
However, the kinetics of the T cell number changes were dif-
ferent when we injected mice with DDA alone: the T cell
number did not increase after the ﬁrst DDA injection. On the
contrary, especially after the second injection of adjuvant
alone, T cell and conventional B cell number changes were
more pronounced than after the second injection of PG in
adjuvant (Fig. 1D and F). Importantly, in the peritoneal cavity
of DBA/2 mice, the DDA injections affected only the B1 cell
Table 1. Immunophenotypic composition of lymphoid cells in
PLF and spleen of naive BALB/c mice
PLF Spleen
T cells (CD3+) 0.172 6 0.039* 19.690 6 1.858*
CD4+ T cells 0.100 6 0.029* 13.820 6 1.337*
CD8+ T cells 0.029 6 0.011* 5.201 6 0.594*
CD4/CD8 3.500 2.657
CD62L
high CD4+ 0.058 6 0.012* 7.286 6 0.883*
CD44




Tregs 0.013 6 0.002* 1.797 6 0.166*
B cells (B220+) 1.779 6 0.272 29.200 6 1.635
B1 cells
a 1.228 6 0.315 3.135 6 0.743
CD5+ B1 cells 0.154 6 0.047* 0.149 6 0.074
CD5 B1 cells 1.063 6 0.036 2.526 6 0.743
CD5+/CD5 0.145 0.059
Conventional B (B2) cells 0.444 6 0.093* 23.330 6 3.715
B1/B2 2.766 0.134
aIn spleen, this population is comprised of transitional B cells,
marginal zone B cells and B1 cells. Numbers represent mean 6 SD of
cell numbers (310
6) of ﬁve independent measurements. Bold-faced
numbers indicate signiﬁcant (P < 0.05) differences when values from
BALB/c and DBA/2 mice (Table 2) are compared (*BALB/c value >
DBA/2 value).
Table 2. Immunophenotypic composition of PLF and spleen
of naive DBA/2 mice
PLF Spleen
T cells (CD3+) 0.052 6 0.010 8.430 6 1.686
CD4+ T cells 0.032 6 0.010 6.575 6 1.349
CD8+ T cells 0.005 6 0.005 1.630 6 0.337
CD4/CD8 6.500 4.034
CD62L
high CD4+ 0.006 6 0.003 1.966 6 0.309
CD44




Tregs 0.005 6 0.001 1.203 6 0.184
B cells (B220+) 1.295 6 0.184 28.887 6 1.068
B1 cells
a 0.875 6 0.370 3.372 6 0.899
CD5+ B1 cells 0.030 6 0.007 0.112 6 0.011
CD5 B1 cells 0.841 6 0.367 3.035 6 0.899
CD5+/CD5 0.035 0.037
Conventional B (B2) cells 0.221 6 0.112 24.335 6 1.686
B1/B2 3.966 0.139
aIn spleen, this population is comprised of transitional B cells,
marginal zone B cells and B1 cells. Numbers represent mean 6 SD of
cell numbers (310
6) of ﬁve independent measurements. Statistical
differences of different cell populations and/or ratios in different
lymphoid compartments are not indicated because the presence of
these cells represents the normal (naive) cell distribution in the PLF
and spleen of naive (non-immunized) DBA/2 mice. Signiﬁcant
differences between BALB/c and DBA/2 are indicated in Table 1.
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tional B cell number to increase as seen in BALB/c mice
(Fig. 1D and F).
In vitro cytokine production by BALB/c PLF cells
Because a signiﬁcant T cell inﬂux was detected in the perito-
neum of BALB/c mice as early as day 10 after the ﬁrst i.p.
injection of PG/DDA and since the number of T cells in the
peritoneum (Fig. 1A) and their activation proﬁle (as mea-
sured by CD25 and CD44) also showed dynamic changes
during the immunization period, we measured cytokines
that are known to be important regulators of the immune
response in PGIA in supernatants of cultured PLF cells
(Fig. 2A).
After the ﬁrst PG injection, on days 5, 10 and 20, there
were measurable amounts of spontaneous IL-12/23 p40,
IL-17 and IFNc in BALB/c PLF cultures (Fig. 2A); the level
of IFNc was elevated after the second PG injection. In re-
sponse to in vitro PG stimulation, PLF cells secreted large
amounts of IFNc, IL-17 and IL-6 and lesser amounts of TNFa
and IL-4 (Fig. 2A). In general, the in vitro cytokine-producing
capacity of PLF cells decreased after the third PG injection,
with TNFa and IL-4 in PG-stimulated PLF cell cultures being
the only exceptions (Fig. 2A).
Fig. 1. Cellular composition changes in the peritoneum of BALB/c (black circles) and DBA/2 (open circles) mice in response to PG immunization
(A, B and C) or repeated DDA adjuvant injections (D, E and F) as assessed by ﬂow cytometry. Time-dependent changes in the number of T (A
and D), B1 (B and E) and conventional B (C and F) cells in the PLF of BALB/c and DBA/2 mice. Values signiﬁcantly higher (*P < 0.05) in BALB/c
than DBA/2, or values that were signiﬁcantly higher (#P < 0.05) or lower (yP < 0.05; in both strains) than in naive animals, are indicated. Data
present mean 6 SEM of three to ﬁve animals at each time point. Arrows on the x-axis (days 0, 21 and 42) indicate the injections. (G) Flow
cytometric contour plots show T cells (green), B1 cells (magenta) and conventional B cells (blue) based on their IgM, IgD, CD19 and CD5
staining in BALB/c mice.
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T cell inﬂux into the peritoneal cavity, we measured the spon-
taneous in vitro cytokine-producing capacity of PLF cells iso-
lated from BALB/c mice injected once with PBS/DDA. We
detected IL-12/23 p40, IL-17, IFNc and TNFa, although in
lesser amounts than in the supernatants of PLF cells of mice
immunized with PG in DDA (data not shown).
In conclusion, BALB/c PLF cells can produce consider-
able amounts of IFNc, IL-17 and IL-12/23 p40, in vitro spon-
taneously, and the levels of these cytokines further increase
upon antigen challenge, except for the IL-12/23 (Fig. 2A).
A similar spontaneous cytokine secretion pattern, with the
exception of IL-4 and IL-6, was found when cells were
harvested from PBS/DDA-injected mice (data not shown).
Cytokines measured in BALB/c spleen cultures
After i.p. injection, antigen is ﬁrst processed by local cells;
however, the systemic response is controlled by the spleen.
Since the direction of the immune response, as determined
by the Th1/Th2 balance, is mainly regulated by pro- and anti-
inﬂammatory cytokines in different lymphatic compartments
(27), we compared cytokine production in non-stimulated and
PG-stimulated spleen cell cultures (Fig. 2B–C; Supplementary
table 1, available at International Immunology Online).
Spleen cells spontaneously secreted relatively large
amounts of IL-6, IL-12/23 p40, IL-17 and IFNc during the en-
tire immunization period (Fig. 2B; Supplementary table 1,
available at International Immunology Online). Increased
production of IL-17 and IFNc was detected as early as 10
days after the ﬁrst PG injection, and IL-17 and IFNc levels
reached a maximum in spleen cell cultures after the second
PG injection (Fig. 2B; Supplementary table 1, available at In-
ternational Immunology Online). Spleen cells from mice that
received only DDA secreted measurable amounts of IL-12/
23 p40, IL-17, IFNc and TNFa 5 and 10 days after a single
DDA injection (data not shown).
Splenic T cell response to PG and serum antibody levels in
BALB/c mice
Next, we monitored the in vitro proliferation responses of
spleen cells to PG (Fig. 2C). BALB/c splenocytes showed
signiﬁcant proliferation upon PG stimulation as early as 5
and 10 days after the ﬁrst PG injection (Fig. 2C), and spleen
cell proliferation further increased after the second and third
PG injections (Fig. 2C). The results of the proliferation
assays correlated with the ratio of activated CD25
high CD4+
T cells in the spleen as assessed by ﬂow cytometry at the
same time points (data not shown).
Fig. 2. Kinetics of the immune response to PG in BALB/c mice. Spontaneous (ctrl) and PG-induced (PG) in vitro cytokine production of PLF (A)
and spleen (B) cell cultures from BALB/c mice (n = 3 animals at each time point). Numbers show the mean cytokine concentrations of
experimental groups (pg 10
6 cells) (mean 6 SEM values are listed in Supplementary table 1, available at International Immunology Online).
Grayscale intensity coding of cytokine concentrations is shown below panel B. (C) In vitro proliferation response measured in the presence of PG
antigen. Values represent D counts per minute (c.p.m.) (PG-stimulated c.p.m.  ctrl c.p.m.) (mean 6 SEM) of spleen cells (n = 3 animals were
sacriﬁced at each time point). (D) Serum IgG1 (black symbols) and IgG2a (white symbols) concentrations against mouse PG (n = 3 animals at
each time point).
516 Peritoneal factors control susceptibility to PGIAIt has been previously shown that in the development of
PGIA, in addition to T cells, antibodies produced by B cells
in response to PG immunization also play an indispensable
role (2, 18). Since cartilage destruction in PGIA is most likely
ampliﬁed by auto-antibody production against mouse carti-
lage PG, we assessed circulating mouse PG-speciﬁc auto-
antibody levels (Fig. 2D). BALB/c mice produced signiﬁcant
amounts of IgG1 and IgG2a to mouse PG after the second
and third PG immunizations (Fig. 2D). As expected, increas-
ing concentrations of IgG1 and IgG2a to human PG were
also detectable in the serum of mice after the second immu-
nization (data not shown).
Comparison of PG-speciﬁc immune responses in BALB/c
and DBA/2 mice
The signiﬁcant difference in the T cell numbers in PLF be-
tween the two strains (Fig. 1A) already indicated that there
could be substantial differences between their immune
responses to PG. Beyond exploring the differences in cellu-
lar composition between the two strains (Tables 1 and 2),
we monitored cytokine and antibody production following re-
peated PG immunization that may have contributed to the
activation of T and B cells and their differentiation into an
arthritogenic phenotype in BALB/c mice (Fig. 2). To decipher
which components of these ‘BALB/c-speciﬁc’ features play
crucial roles in PGIA susceptibility, we made a systematic
comparison with arthritis-resistant DBA/2 mice using approx-
imately the same number of animals and exactly the same
immunization protocol. Although the DBA/2 strain carries the
same MHC (H-2d) as the BALB/c strain, DBA/2 mice are re-
sistant to PGIA (2, 18, 24).
The in vitro cytokine production proﬁle of PLF cells har-
vested from DBA/2 mice (Fig. 3A) was fundamentally dif-
ferent from that of BALB/c (Fig. 2A). IL-6 was the most
dominant cytokine at all time points of the immunization pro-
tocol in DBA/2 PLF cell cultures, whereas minimal or no
IL-4, IL-12/23 p40, IL-17 or IFNc production was detected
(Fig. 3A). DBA/2 spleen cells produced signiﬁcantly less
IL-17 and IFNc at almost all time points after immunization
than BALB/c splenocytes (Figs 3B and 2B; Supplementary
table 1, available at International Immunology Online).
DBA/2 spleen cultures exhibited higher in vitro prolifera-
tion responses to PG when compared with identical BALB/c
cell cultures between the second and third immunizations
(Fig. 3C). However, after the third immunization, this spleen
cell proliferation capacity declined (Fig. 3C). The auto-anti-
body levels against mouse PG in the sera of DBA/2 mice
were only 10–30% of those measured in BALB/c mice when
compared at the same time points of immunization (compare
Fig. 3D with Fig. 2D).
Fig. 3. Kinetics of the immune response to PG in DBA/2 mice. In vitro cytokine production of PLF (A) and spleen (B) cells. Numbers show the
mean cytokine concentrations of experimental groups (pg 10
6 cells). Grayscale intensity coding is shown below the spleen panel. (C) In vitro
Tcell proliferation in response to PG stimulation. Bars represent D counts per minute (c.p.m.) (PG-stimulated c.p.m.  ctrl c.p.m.) (mean 6 SEM)
of spleen cells (n = 3 animals at each time point). (D) Serum IgG1 (black symbols) and IgG2a (white symbols) concentrations against mouse PG
(n = 3 animals at each time point) in DBA/2 mice. Note, the y-axis scale is the same as in Fig. 2(D).
Peritoneal factors control susceptibility to PGIA 517Transfer of PGIA to SCID mice with PLF cells from BALB/c
mice
PGIA can be adoptively transferred into syngeneic SCID
mice using spleen cells from arthritic BALB/c donors and
PG antigen (20). Side-by-side comparison of BALB/c and
DBA/2 immune responses to PG revealed the most pro-
nounced difference in T cells and their cytokine production
in the peritoneal cavity. Since the arthritogenic potential of
peritoneal cells from PG-immunized BALB/c mice has never
been tested, we injected PLF cells, comprised mostly of
T cells and conventional B cells and some B1 cells (Fig. 1).
The results of the transfer experiments are summarized in
Table 3. PGIA was transferred most efﬁciently (100% inci-
dence, highest arthritis score) with PLF cells from arthritic
BALB/c mice (Table 3, Group C). Importantly, transfer of
PGIA was also possible with PLF cells harvested 10 days af-
ter the second i.p. injection from not yet arthritic BALB/c
mice (Table 3, Group B). There was no arthritis at all in the
SCID recipients when PLF cells harvested from mice immu-
nized only once with PG and DDA were transferred (Table
3, Group A). PLF cells from DBA/2 mice induced mild arthri-
tis (using the same conditions) only after repeated (four
times) PG/DDA injections (data not shown).
SCID mice were sacriﬁced 45 days after the second cell
transfer, and cells from PLF and spleen were harvested.
Flow cytometric analysis revealed that these compartments
in all SCID recipients were efﬁciently repopulated with donor
BALB/c PLF lymphocytes, mainly T cells (most of which were
CD44
high CD4+), conventional B cells and B1 cells (Fig. 4A
and B; Supplementary table 2, available at International Im-
munology Online). Moreover, large proportions of both T and
B cells expressed CD69 and CD25 activation markers at
high levels (Fig. 4C and D; Supplementary table 2, available
at International Immunology Online).
PG-induced in vitro T cell proliferation was highest in
Group C SCID mice (Table 3). In vitro production of IL-4
and IL-6 by spleen cells upon PG stimulation was signiﬁ-
cantly higher in Group C than in Group A or B (Table 3).
IFNc and IL-17 productions were only detectable in spleen
cultures of Group C (Table 3). Serum IgG1 to both human
and mouse PG was highest in Group C, while IgG2a to hu-
man PG was only detectable in Group C (Table 3).
In summary, we found that BALB/c PLF cells co-injected
with antigen were able to transfer PGIA to SCID hosts even
if the cells were harvested from twice-immunized, but not
yet arthritic, donor mice. Importantly, these PLF cells were
already committed to be highly arthritogenic, since the trans-
fer of 1–3 3 10
6 cells was sufﬁcient to induce arthritis,
whereas conventional transfer usually required 1–2 3 10
7
spleen cells from severely arthritic BALB/c mice (20).
Discussion
In this study, we have analyzed and compared the distribu-
tion of T and B lymphocytes and their responses to PG im-
munization in PLF and spleen of arthritis-susceptible BALB/c
and arthritis-resistant DBA/2 mice. The early changes in-
duced by PG immunization in these tissue compartments,
especially in the peritoneal cavity, most likely led to the dif-
ferentiation and activation of arthritogenic T and B cells
which then triggered synovial joint inﬂammation in BALB/c
mice. The adjuvant (DDA) proved to be a major contributor
to these early cellular changes, but DDA alone was insufﬁ-
cient to induce any inﬂammatory reaction in synovial joints
as conﬁrmed by histology.
Relatively, early after the ﬁrst i.p. immunization, there was
a robust T cell inﬂux and/or proliferation in the peritoneal
cavity in BALB/c mice, accompanied by the disappearance
of the resident naive B1 cell population. Upon repeated
immunizations, this skew in the cellular composition became
more apparent. The continuously elevated T cell numbers
were most likely the result of both the homing of antigen-
speciﬁc T cells to the peritoneum and the local expansion of
resident T cells. This notion is further supported by the fact
that the absence of neither CD44 nor CD62L molecules [in
knockout (KO) mice] could completely abolish the T cell
number increase in the peritoneal cavity (data not shown).
The transient decrease in T cell number after the second
PG/DDA injection might be the result of the systemic (joint)
recirculation of autoreactive T cells and activation-induced
cell death locally in the peritoneal cavity (28). The T cell-
enriched peritoneal effusion in BALB/c mice, which could
not be detected in arthritis-resistant DBA/2 mice, might well









Incidence (arthritic/total) 0/3 2/3 4/4
Onset
a NA 19–31 19–22
Maximum arthritic score NA 5.5 6 1.5 6.8 6 1.5
In vitro spleen cell
proliferation
b
1.5 6 0.2 0.8 6 0.02 2.3 6 0.6




IL-4 214 6 33 143 6 96 457 6 26*
IL-6 111 6 17 182 6 103 532 6 63*
IL-17 ND ND 532 6 64
IFNc ND ND 1343 6 73
TNFa 42 6 27 200 6 180 157 6 109
Serum antibodies to
hu PG IgG (mg ml
1) ND 2.6 6 1.1 6.2 6 1.1*
hu PG IgG2a (mg ml
1) ND ND 0.21 6 0.11
mPG IgG1 (lg ml
1) 8.9 6 8.7 12.7 6 12.5 70 6 11.3*
mPG IgG2a (lg ml
1) 46.3 6 45.5 ND ND
PLF cells from BALB/c donors after one, two or three PG
immunizations were injected with PG into SCID recipients. Transfers
were repeated after 14 days. Table shows the incidence, onset and
arthritis score of transferred SCID mice, the in vitro measured
immunologic parameters (PG-speciﬁc T cell proliferation and
cytokine production) and serum antibody levels in recipients at the
end of transfer experiments (45 days after the second transfer). All
values are shown as mean 6 SEM. Numbers in bold face (Group C)
indicate signiﬁcant (*P < 0.05) differences when compared with either
Group A or B. NA, not applicable; ND, not detected; hu PG, human
PG; mPG, mouse PG.
aDays after the second transfer.
bSI, stimulation index.
518 Peritoneal factors control susceptibility to PGIAbe one of the critical upstream contributors that set the
stage for the development of PGIA.
In BALB/c mice, a dominant production of pro-inﬂammatory
cytokines (IL-6, IL-12/23 p40, IFNc,I L - 1 7a n dT N F a)w a s
already detected at the early stages of i.p. immunization-
induced peritonitis at 5 and 10 days following the ﬁrst i.p. in-
jection. This was not due to the injection itself, because i.p.
injection of 200 ll PBS did not induce cytokine production
and had no evident effect upon peritoneal cell composition
(our unpublished data). The massive shift in cellular composi-
tion and cytokine production in PLF, which might be due to
the combined effects of adjuvant and strain speciﬁc factors,
may dictate arthritis susceptibility in BALB/c and resistance in
DBA/2 mice.
IL-12 and IL-27 have been shown to promote Th1 differen-
tiation, whereas IL-6, transforming growth factor b and IL-23
(which shares a common p40 chain with IL-12) promote and
maintain the Th17 lineage (29, 30). Both Th1 and Th17 cyto-
kines have been associated with arthritis in different mouse
models (21, 31). Th1 dominance was shown to be character-
istic of PGIA (21, 22), whereas the absence of IL-17 alone in
IL-17a-deﬁcient BALB/c mice did not seem to have a signiﬁ-
cant effect on PGIA (32). Nonetheless, IL-17 has been
shown to be an important mediator in human RA (33, 34),
collagen-induced arthritis (35) and spontaneous arthritis in
either SKG (36) or IL-1 receptor antagonist-deﬁcient mice
(37), as well as in experimental autoimmune encephalomy-
elitis (38). In contrast to the in vivo experiments in which
IL-17a deﬁciency alone seems to play a limited role in PGIA
(32, 39), we show that one of the prominent cytokines pro-
duced during the PG immunization period is IL-17 in BALB/
c mice. This suggests that in addition to IFNc, IL-17 might
play a role in PGIA similar to its implicated role in other auto-
immune disease models and RA. Indeed, IFNc and IL-17
were the cytokines that were produced in signiﬁcantly lesser
amounts at most time points (especially by the PLF cells) in
the resistant DBA/2 strain, suggesting that high levels of
IFNc and IL-17 might contribute to PGIA susceptibility.
Results obtained in IFNc and IL-17 double KO mice (A.
Finnegan, personal communication) revealed the role of
IL-17 in PGIA. While IFNc is a key cytokine in PGIA, IFNc de-
ﬁciency alone does not abolish completely PGIA. This ‘resid-
ual arthritis’, however, is completely eliminated by additional
IL-17 deﬁciency. Thus, the absence of IL-17 in the IL-17a-
deﬁcient mice most likely is compensated by IFNc. In turn,
in wild-type BALB/c mice, both cytokines are present and in-
volved in PGIA.
B cells are excellent APCs (40), and B cells from PG-
immunized BALB/c mice are 1000 times more effective APCs
than peritoneal macrophages (4, 41). Antigen presentation is
known to inﬂuence both the magnitude and the direction of
the immune response (42). It has been shown recently
that B1 and conventional B (B2) cells induce different path-
ways of T cell differentiation (11). According to Zhong et al.
(11), when B1 cells were used as APCs under in vitro con-
ditions, Th1/Th17 cells accumulated, whereas conventional
B cells as APCs induced the proliferation of Tregs. In naive
(non-immunized) conditions, the peritoneal cavity is rich in B1
cells (Fig. 1 and Table 1), and these B1 cells, through antigen
presentation, may initially direct the immune response toward
Th1/Th17 differentiation. Although the number of B1 cells
decreases upon repeated PG/DDA injections, a low number
of B1 cells may be sufﬁcient for maintaining the polarization
and dominance of Th1 and Th17 CD4+ cells in the peritoneal
cavity of BALB/c mice. In contrast, conventional B2 cells rep-
resent the majority of B cells in spleen of DBA/2 mice. This
may be one of the reasons for the expansion of the splenic
Treg population detected at day 5 after the ﬁrst PG injection
in DBA/2 mice (data not shown). Similar expansion of splenic
Tregs was also observed by Zhong et al. (11). This early Treg
induction in the spleen could also contribute to the PGIA-
resistant phenotype of the DBA/2 mouse strain.
Fig. 4. Flow cytometric evaluation of cellular reconstitution in SCID recipients after transfer of PLF cells from arthritic BALB/c donors (Table 3,
Group C). (A and B) Representative ﬂow cytometric contour plots show the cellular composition of PLF and spleen of SCID recipients. (C and D)
Activation marker (CD69 and CD25) expression of T and B cells is shown on histograms (T cells: green and B cells: magenta). Corresponding
data (PG-induced Tcell proliferation, PG-induced in vitro cytokine production and serum antibodies to human and mouse PG) of SCID recipients
from all groups are summarized in Table 3, and more detailed information for cellular composition of PLF and spleen are summarized in
Supplementary table 2 (available at International Immunology Online).
Peritoneal factors control susceptibility to PGIA 519Upon the second PG injection, T and B cells are reacti-
vated in the peritoneal cavity, and this event is accompanied
by a robust change in the T and B cell composition and acti-
vation state (Fig. 1). This change is reﬂected by the produc-
tion of IFNc, IL-17 and auto-antibodies against mouse PG
in BALB/c, but not in DBA/2 mice. These PG-speciﬁc auto-
antibodies, together with activated effector Th1 and Th17
cells, may ﬁnd their targets in the joints (5, 41, 43). Deposi-
tion of PG-speciﬁc antibodies in the joints and T cell mig-
ration to the synovium, also indicated by the transient
decrease in the T cell number of the PLF 10 days after
the second PG + DDA injection, may trigger the effector
phase of autoimmune arthritis, amplifying the local response
through pro-inﬂammatory cytokine (IL-1b, TNFa, IFNc, IL-17
and IL-6) production, thereby leading to progressive joint tis-
sue destruction. Since in DBA/2 mice there was signiﬁcantly
less inﬂux of T cells into the peritoneal cavity, T cell help was
probably not sufﬁcient for auto-antibody production. Subtle
differences in co-stimulation, which might inﬂuence the T–B
cell interactions, cannot be ruled out between the two
strains. Our PLF cell transfer experiments show that boosting
peritoneal cells with a second PG injection in donor BALB/c
mice enhanced the arthritogenic potential of these cells in
SCID recipients. This supports the hypothesis that, although
PG-primed T and B cells already appear in the peritoneum
after the ﬁrst immunization, their reactivation via clonal ex-
pansion is necessary to reach the fully ‘armed effector’ state.
A potentially interesting implication of this study is the
importance of the peritoneal lymphoid cells in controlling au-
toimmune joint inﬂammation. B1 cells, residing in the perito-
neal cavity, have been implicated in autoimmunity (44). They
produce auto-antibodies spontaneously at low concentra-
tions, and these cells may be considered as physiological
regulators of autoimmunity (45). Although there is no direct
evidence for their role in RA so far, it might be interesting to
speculate that changes in the physiological peritoneal milieu
in susceptible humans, similar to what happens in BALB/c
mice as a consequence of i.p. PG/DDA injections, could
pave the way to autoimmune joint inﬂammation. Theoreti-
cally, repeated peritoneal antigen (endogenous or exoge-
nous) stimuli, together with chronic exposure to chemicals
with potential adjuvant activity, might contribute to such
cellular changes, eventually leading to impaired immune
regulation.
A key observation of this study is that injection of adjuvant
(DDA) alone induced very similar changes in peritoneal cell
composition as the injection of DDA with PG. However, only
BALB/c mice injected with PG/DDA developed strong anti-
gen-speciﬁc immune responses and arthritis. DDA has been
shown to skew the immune response toward the Th1 direc-
tion (46, 47) in addition to strongly activating innate immune
cells (14). Here, we show that DDA induces the recruitment
of T cells into the peritoneum, which is in line with earlier
observations (17), but the kinetics of T cell inﬂux was dif-
ferent when the antigen was present (Fig. 1). This effect,
however, can be attributable to the local induction of inﬂam-
matory adhesion molecules and chemokines. The propensity
of these T cells to produce IFNc, TNFa, IL-12 and IL-17 in the
early stage of immunization may create an optimal milieu for
the differentiation and activation of autoimmune T and B cells
when antigen (PG) is present. Such peritoneal T cell re-
sponse was lacking in DBA/2 mice, which raises the possi-
bility that the adjuvant itself might not effectively activate
innate immune cells in this strain. On the contrary, systemic
T cell response and serum antibody levels against the immu-
nizing antigen showed that the immunization was effective,
although at different levels, in both strains. This correlates
with earlier studies which have shown that DBA/2 mice, simi-
lar to BALB/c, are good responders to DDA (48).
As we have shown, PGIA resistance in DBA/2 mice is not
the consequence of the lack of the systemic immune re-
sponse against the immunizing (human) PG. However, the
‘autoimmune switch’ and the subsequent immune attack on
the joints (self-PG) can only be observed in BALB/c mice.
Our preliminary transfer experiments with PLF cells from
hyper-immunized DBA/2 mice also support the idea that
indeed, DBA/2 cells carry some arthritogenic potential,
which, otherwise, is suppressed in the original wild-type
background. Several candidate molecules can be involved
in the development of autoimmunity, including innate im-
mune receptors, like Toll-like receptors (TLRs) (49, 50), and
co-stimulatory molecules (51). For example, ﬂow cytometry
analysis has shown that higher percentage of peritoneal
macrophages express TLR1 in DBA/2 than in BALB/c mice
(data not shown).
Therefore, we conclude that the arthritis-susceptible phe-
notype of BALB/c mice is due to an autoimmune switch dur-
ing the immunization with human PG. This is potentially
determined by differences in the adjuvant response, locally,
in the peritoneal cavity and in joint-draining lymph nodes of
BALB/c mice with PGIA (4). The profound immunopheno-
typic differences between the two strains found here, in ad-
dition to data from genetic studies (2, 52), may advance our
understanding of the critical events leading to autoimmunity
in PGIA in the BALB/c strain.
Supplementary data
Supplementary tables are available at International Immunology
Online.
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PG proteoglycan
PGIA PG aggrecan-induced arthritis
PLF peritoneal lavage ﬂuid
RA rheumatoid arthritis
SEM standard error of the mean
TNFa tumor necrosis factor
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